64P Neoadjuvant Toripalimab Plus Chemotherapy in Patients with Potentially Resectable Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Trial (renaissance Study)
S. Yan,J. Chen,J. Wang,C. Lv,J. Bi,X. Yang,S. Li,Y. Wang,X. Li,Y. Yang,N. Wu
DOI: https://doi.org/10.1016/j.annonc.2021.10.082
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundTreatment combination of immune checkpoint inhibitor (ICI) and platinum-based chemotherapy have displayed promising anti-tumor activities in resectable non-small cell lung cancer (NSCLC). We designed a phase II trial to elucidate the safety and feasibility of toripalimab (a PD-1 inhibitor) plus double platinum-based chemotherapy as neoadjuvant treatment for potentially resectable NSCLC.MethodsStudy eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC pts with ECOG PS 0-1 status. Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy before surgery. After the second treatment cycle, imaging/surgical indication evaluation were performed within 3 weeks. Pts who cannot undergo surgery will be reassessed after another 1-2 cycles of neoadjuvant therapy. Primary endpoints were major pathological response (MPR), objective response rate (ORR) and safety. Secondary endpoints were R0 resection rate and progression-free survival (PFS).ResultsA total of 21 eligible pts (median age: 62, IQR: 45-74; female: 2, 9.5%; smoking history: 18, 85.7%) were enrolled and received neoadjuvant treatment (2 cycles: 18 pts; 3 cycles: 3 pts) since Mar 2021. Histopathological diagnosis identified 16 pts with squamous cell carcinoma, 3 pts with adenocarcinoma and 2 pts with adenosquamous carcinoma. Disease distribution in stage IIB, IIIA and IIIB consisted of 6, 11 and 4 pts, respectively. 19 pts (19/21, 90.5%) underwent resection (median interval between neoadjuvant treatment and surgery: 67 days, IQR 40-113), 2 pts were unsuitable for surgery. The R0 resection rate was 100%. 11 patients (11/19, 57.9%) achieved MPR, including 7 patients (7/19, 36.8%) with pCR. No patient had surgical complications. Grade 3-4 treatment-related adverse events (TRAEs) included one (1/21, 4.5%) patient with grade 3 leukopenia and grade 4 neutrophilopenia. Grade 1-2 TRAEs were reported in 14 patients (14/21, 66.7%).ConclusionsNeoadjuvant toripalimab plus platinum-based doublet is tolerable and effective for pts with potentially resectable NSCLC.Clinical trial identificationNCT04606303.Legal entity responsible for the studyThe authors.FundingJunshi Biosciences.DisclosureAll authors have declared no conflicts of interest. BackgroundTreatment combination of immune checkpoint inhibitor (ICI) and platinum-based chemotherapy have displayed promising anti-tumor activities in resectable non-small cell lung cancer (NSCLC). We designed a phase II trial to elucidate the safety and feasibility of toripalimab (a PD-1 inhibitor) plus double platinum-based chemotherapy as neoadjuvant treatment for potentially resectable NSCLC. Treatment combination of immune checkpoint inhibitor (ICI) and platinum-based chemotherapy have displayed promising anti-tumor activities in resectable non-small cell lung cancer (NSCLC). We designed a phase II trial to elucidate the safety and feasibility of toripalimab (a PD-1 inhibitor) plus double platinum-based chemotherapy as neoadjuvant treatment for potentially resectable NSCLC. MethodsStudy eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC pts with ECOG PS 0-1 status. Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy before surgery. After the second treatment cycle, imaging/surgical indication evaluation were performed within 3 weeks. Pts who cannot undergo surgery will be reassessed after another 1-2 cycles of neoadjuvant therapy. Primary endpoints were major pathological response (MPR), objective response rate (ORR) and safety. Secondary endpoints were R0 resection rate and progression-free survival (PFS). Study eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC pts with ECOG PS 0-1 status. Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy before surgery. After the second treatment cycle, imaging/surgical indication evaluation were performed within 3 weeks. Pts who cannot undergo surgery will be reassessed after another 1-2 cycles of neoadjuvant therapy. Primary endpoints were major pathological response (MPR), objective response rate (ORR) and safety. Secondary endpoints were R0 resection rate and progression-free survival (PFS). ResultsA total of 21 eligible pts (median age: 62, IQR: 45-74; female: 2, 9.5%; smoking history: 18, 85.7%) were enrolled and received neoadjuvant treatment (2 cycles: 18 pts; 3 cycles: 3 pts) since Mar 2021. Histopathological diagnosis identified 16 pts with squamous cell carcinoma, 3 pts with adenocarcinoma and 2 pts with adenosquamous carcinoma. Disease distribution in stage IIB, IIIA and IIIB consisted of 6, 11 and 4 pts, respectively. 19 pts (19/21, 90.5%) underwent resection (median interval between neoadjuvant treatment and surgery: 67 days, IQR 40-113), 2 pts were unsuitable for surgery. The R0 resection rate was 100%. 11 patients (11/19, 57.9%) achieved MPR, including 7 patients (7/19, 36.8%) with pCR. No patient had surgical complications. Grade 3-4 treatment-related adverse events (TRAEs) included one (1/21, 4.5%) patient with grade 3 leukopenia and grade 4 neutrophilopenia. Grade 1-2 TRAEs were reported in 14 patients (14/21, 66.7%). A total of 21 eligible pts (median age: 62, IQR: 45-74; female: 2, 9.5%; smoking history: 18, 85.7%) were enrolled and received neoadjuvant treatment (2 cycles: 18 pts; 3 cycles: 3 pts) since Mar 2021. Histopathological diagnosis identified 16 pts with squamous cell carcinoma, 3 pts with adenocarcinoma and 2 pts with adenosquamous carcinoma. Disease distribution in stage IIB, IIIA and IIIB consisted of 6, 11 and 4 pts, respectively. 19 pts (19/21, 90.5%) underwent resection (median interval between neoadjuvant treatment and surgery: 67 days, IQR 40-113), 2 pts were unsuitable for surgery. The R0 resection rate was 100%. 11 patients (11/19, 57.9%) achieved MPR, including 7 patients (7/19, 36.8%) with pCR. No patient had surgical complications. Grade 3-4 treatment-related adverse events (TRAEs) included one (1/21, 4.5%) patient with grade 3 leukopenia and grade 4 neutrophilopenia. Grade 1-2 TRAEs were reported in 14 patients (14/21, 66.7%). ConclusionsNeoadjuvant toripalimab plus platinum-based doublet is tolerable and effective for pts with potentially resectable NSCLC. Neoadjuvant toripalimab plus platinum-based doublet is tolerable and effective for pts with potentially resectable NSCLC.